GSK (NYSE:GSK) PT Raised to $53.00

GSK (NYSE:GSK) had its price target hoisted by investment analysts at Jefferies Financial Group from $52.50 to $53.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the pharmaceutical company’s stock. Jefferies Financial Group’s price objective indicates a potential upside of 39.51% from the stock’s previous close.

A number of other brokerages have also recently weighed in on GSK. Berenberg Bank upgraded GSK to a “strong-buy” rating in a research note on Thursday, June 20th. Citigroup upgraded GSK to a “strong-buy” rating in a research report on Monday, June 24th. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Finally, The Goldman Sachs Group started coverage on shares of GSK in a report on Thursday, May 30th. They issued a “neutral” rating and a $47.00 target price for the company. One analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $50.00.

GSK Trading Down 1.0 %

GSK stock traded down $0.39 during midday trading on Tuesday, reaching $37.99. 1,509,709 shares of the stock traded hands, compared to its average volume of 3,638,864. The firm has a market cap of $78.73 billion, a PE ratio of 13.76, a price-to-earnings-growth ratio of 1.16 and a beta of 0.64. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.15. The company has a 50-day simple moving average of $42.51 and a two-hundred day simple moving average of $41.23. GSK has a 12-month low of $33.67 and a 12-month high of $45.92.

GSK (NYSE:GSK) last released its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.15. The company had revenue of $9.34 billion for the quarter, compared to analyst estimates of $8.98 billion. GSK had a net margin of 14.62% and a return on equity of 51.54%. Research analysts expect that GSK will post 4.11 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc raised its position in shares of GSK by 2,816.7% in the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 676 shares during the last quarter. Register Financial Advisors LLC purchased a new position in shares of GSK during the 1st quarter worth $31,000. BKM Wealth Management LLC acquired a new stake in shares of GSK during the fourth quarter worth $32,000. Richardson Financial Services Inc. purchased a new stake in shares of GSK in the fourth quarter valued at $40,000. Finally, Newbridge Financial Services Group Inc. acquired a new position in GSK in the first quarter valued at $49,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.